Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Preclinical Models & Translational Research
Preclinical Models & Translational Research
Type here to filter the list
(P 246) IMMUNOCOMPETENT MODELING OF PLEOMORPHIC LIPOSARCOMA
Favorite
(P 247) HARNESSING EWING SARCOMA'S REPLICATION STRESS BY TARGETING DDK AND WEE1 IN COMBINATION
Favorite
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Favorite
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Favorite
(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY
Favorite
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Favorite
(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Favorite
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Favorite
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Favorite
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Favorite
(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).
Favorite
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
Favorite
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Favorite
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Favorite
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Favorite
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Favorite
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Favorite
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Favorite
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Favorite
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Favorite
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Favorite
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Favorite
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Favorite
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Favorite
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Favorite
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Favorite
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Favorite
(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE
Favorite
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Favorite
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Favorite
(P 284) VALIDATING A NOVEL MICROFLUIDIC PLATFORM AS AN EX VIVO TUMOUR MODEL FOR SARCOMA DRUG DISCOVERY
Favorite
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Favorite
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Favorite
(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR
Favorite
(P 288) EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN
Favorite
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Favorite
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Favorite
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Favorite
(P 292) APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY
Favorite
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Favorite
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Favorite
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Favorite
(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA
Favorite
(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA
Favorite
(P 300) ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS
Favorite
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Favorite
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Favorite
(P 304) A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS
Favorite
(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA
Favorite
